News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Conference News AHA 2022 SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint Todd Neale November 09, 2022
Presentation AHA 2022 Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial Presenter: David E. Kandzari November 07, 2022
News Daily News SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes Michael O'Riordan October 18, 2022
News Conference News TCT 2022 SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss Michael O'Riordan September 19, 2022
News Conference News TCT 2022 RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP Todd Neale September 18, 2022
News Daily News RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation Todd Neale July 26, 2022
Presentation EuroPCR 2022 Blood pressure and MACE reductions after renal denervation: 3-year GSR results Presenter: Felix Mahfoud May 20, 2022
News Conference News EuroPCR 2022 Registry Data Hint at MACE Benefit With Renal Denervation Michael O'Riordan May 17, 2022
News Opinion Editor's Corner EuroPCR 2022 EuroPCR Kicks Off In Person Next Week in Paris: Here’s What to Expect Shelley Wood May 12, 2022
Presentation ARCH 2022 Current Status and Future of Renal Denervation for Hypertension Presenter: Tim A. Fischell April 23, 2022
News Conference News ACC 2022 SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures Todd Neale April 08, 2022
Presentation ACC 2022 Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial Presenter: Felix Mahfoud April 04, 2022